文献速递泌尿男性生殖肿瘤

帕博利珠单抗联合方案一线治疗晚期透明细胞肾细胞癌:KEYMAKER-U03子研究03A

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
PubMed 文献 · Ann Oncol · 2025-10-18

KEYMAKER-U03子研究03A是一项I/II期平台试验,评估五种含帕博利珠单抗方案一线治疗晚期透明细胞肾细胞癌的疗效与安全性。393例患者随机分配,帕博利珠单抗+仑伐替尼的ORR为80.6%,帕博利珠单抗+仑伐替尼+belzutifan的ORR为77.5%且中位PFS达31.8个月,各组≥3级治疗相关不良事件发生率在68.9%至86.9%之间。

要点

  • 帕博利珠单抗+仑伐替尼一线治疗ORR达80.6%,中位PFS 26.3个月。
  • 加用belzutifan后中位PFS达31.8个月,ORR 77.5%。
  • vibo/pembro+bel组ORR仅42.5%,劣于参考组。

核心结论

  • 帕博利珠单抗+仑伐替尼的疗效与安全性与此前观察一致。
  • 帕博利珠单抗+仑伐替尼+belzutifan和qmab/pembro+仑伐替尼的ORR与参考组相似,其他试验组则不然。
  • 帕博利珠单抗+仑伐替尼+belzutifan和qmab/pembro+仑伐替尼对比帕博利珠单抗+仑伐替尼的进一步研究正在III期LITESPARK-012中进行。

研究设计与样本

  • KEYMAKER-U03子研究03A是一项开放标签、伞式平台、I/II期试验(NCT04626479)。
  • 入组晚期透明细胞肾细胞癌且未接受过系统治疗的患者,按2:1随机分配至五种含帕博利珠单抗方案或对照方案。
  • 所有试验组在随机化前进行约10例患者的安全性导入。
  • 主要终点为盲法独立中心审查按RECIST v1.1评估的ORR(全部随机患者,排除安全性导入)和安全性(全部治疗患者)。
  • 截至2025年3月31日共入组393例患者,随机患者中位随访时间在各队列间为16至39个月。

主要发现

  • 帕博利珠单抗+仑伐替尼组ORR为80.6%(95%CI 68.6%-89.6%),中位PFS 26.3个月(95%CI 15.3-39.8个月)。
  • qmab/pembro+仑伐替尼组ORR为71.3%(95%CI 60.0%-80.8%),中位PFS 18.0个月(95%CI 11.6-34.3个月)。
  • fave/pembro+仑伐替尼组ORR为62.7%(95%CI 48.1%-75.9%),中位PFS 26.0个月(95%CI 8.2-31.8个月)。
  • 帕博利珠单抗+仑伐替尼+belzutifan组ORR为77.5%(95%CI 66.8%-86.1%),中位PFS 31.8个月(95%CI 26.3个月-NR)。
  • vibo/pembro+belzutifan组ORR为42.5%(95%CI 31.5%-54.1%),中位PFS 15.2个月(95%CI 12.4个月-NR)。

关键数值与推荐

  • 帕博利珠单抗+仑伐替尼组≥3级治疗相关不良事件发生率为71.0%(44/62)。
  • qmab/pembro+仑伐替尼组≥3级治疗相关不良事件发生率为73.3%(66/90)。
  • fave/pembro+仑伐替尼组≥3级治疗相关不良事件发生率为86.9%(53/61)。
  • 帕博利珠单抗+仑伐替尼+belzutifan组≥3级治疗相关不良事件发生率为70.0%(63/90)。
  • vibo/pembro+belzutifan组≥3级治疗相关不良事件发生率为68.9%(62/90)。

临床怎么用

  • 帕博利珠单抗+仑伐替尼可作为晚期透明细胞肾细胞癌一线治疗的参考方案。
  • 帕博利珠单抗+仑伐替尼+belzutifan和qmab/pembro+仑伐替尼显示出与参考组相似的ORR,需等待III期试验进一步验证。
  • vibo/pembro+belzutifan方案疗效较差,不推荐用于一线治疗。

局限性

  • 本研究为I/II期平台试验,样本量有限且各组随访时间不一致。
  • 主要终点为ORR和安全性,PFS和OS为次要终点且中位OS尚未达到。
  • 各组间疗效比较未提供统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line triplet therapy may expand clinical benefit for advanced clear-cell renal cell carcinoma (ccRCC). The phase Ib/II KEYMAKER-U03 substudy 03A (NCT04626479) investigated novel pembrolizumab (pembro)-based regimens in this setting. PATIENTS AND METHODS: Participants with advanced ccRCC and no prior systemic therapy were randomized 2 : 1 to quavonlimab (qmab)/pembro plus lenvatinib (lenva), favezelimab (fave)/pembro plus lenva, pembro plus lenva plus belzutifan (bel), and vibostolimab (vibo)/pembro plus bel or a concurrent reference treatment (pembro plus lenva). A safety lead-in of ∼10 participants occurred for all investigative treatments before randomization. Primary endpoints were objective response rate (ORR) per RECIST v1.1 by blinded independent central review in all randomized participants (excluding safety lead-in), and safety in all treated participants. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). RESULTS: As of 31 March 2025, 393 participants were enrolled. Median follow-up for randomized participants across the five cohorts ranged between 16 and 39 months. The ORR was 80.6% [95% confidence interval (CI) 68.6% to 89.6%] with pembro plus lenva, 71.3% (95% CI 60.0% to 80.8%) with qmab/pembro plus lenva, 62.7% (95% CI 48.1% to 75.9%) with fave/pembro plus lenva, 77.5% (95% CI 66.8% to 86.1%) with pembro plus lenva plus bel, and 42.5% (95% CI 31.5% to 54.1%) with vibo/pembro plus bel. Median PFS was 26.3 months (95% CI 15.3-39.8 months) with pembro plus lenva, 18.0 months (95% CI 11.6-34.3 months) with qmab/pembro plus lenva, 26.0 months (95% CI 8.2-31.8 months) with fave/pembro plus lenva, 31.8 months [95% CI 26.3 months-not reached (NR)] with pembro plus lenva plus bel, and 15.2 months (95% CI 12.4 months-NR) with vibo/pembro plus bel. Median OS was not reached in any arm. Grade ≥3 treatment-related adverse events occurred in 71.0% (44/62) of participants treated with pembro plus lenva, 73.3% (66/90) with qmab/pembro plus lenva, 86.9% (53/61) with fave/pembro plus lenva, 70.0% (63/90) with pembro plus lenva plus bel, and 68.9% (62/90) with vibo/pembro plus bel. CONCLUSIONS: Observed efficacy and safety of pembro plus lenva were confirmatory of prior observations for this combination. ORR was similar to reference for pembro plus lenva plus bel and qmab/pembro plus lenva, but not the other investigative arms. Further investigation of pembro plus lenva plus bel and qmab/pembro plus lenva versus pembro plus lenva is ongoing in the phase III LITESPARK-012 study.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Suarez C, Rojas C, Shin SJ, et al. Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial. Ann Oncol. 2025. PMID: 41115468. doi:10.1016/j.annonc.2025.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。